Clinical Study of DMT in Healthy Adults

Inhaled N, N-Dimethyltryptamine: a Phase I Study in Healthy Adults

This study aims to evaluate the acute and subacute effects of an inhaled N, N-Dimethyltryptamine in healthy individuals.

Participants will receive N, N-Dimethyltryptamine administered in two dosing sessions: an initial low-dose safety session and subsequent intermediate-dose treatment, in a fixed order and 2h apart.

Inclusion Criteria:

• prior experience with N,N-Dimethyltryptamine (DMT)
• present proof of vaccination against COVID-19 (Coronavírus)

Exclusion Criteria:

• heart failure
• liver failure
• kidney failure
• resistant hypertension
• arrhythmia
• valvular heart disease
• chronic obstructive pulmonary disease
• asthma
• severe obesity
• epilepsy
• pregnancy
• thyroid disorders
• family diagnosis or suspicion of genetic monoamine oxidase deficiency
• previous adverse response to psychedelic substances
• present or past symptoms or family members with a psychotic disorder
• dissociative identity disorder
• bipolar disorder
• prodromal symptoms of schizophrenia
• abuse of alcohol or other psychoactive substances, except tobacco
• acute or sub-acute risk of suicide
• flu-like symptoms